Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity

150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention

The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to 75 mg clopidogrel after elective percutaneous coronary intervention.

Inclusion Criteria:

• Clopidogrel-naïve stable angina pectoris (CCS I-III)
• Coronary angiography that reveals significant DE NOVO coronary stenosis (diameter stenosis greater than 50% in two independent projections) feasible for ad hoc stent implantation

Exclusion Criteria:

• Acute coronary syndrome (STEMI, NSTEMI or unstable angina)
• Administration of clopidogrel/ticlopidine/coumarin in the past 6 weeks
• Contraindication to antiplatelet therapy
• Significant LM stenosis
• PCI due to instent restenosis
• Lesion located in bypass grafts
• Stroke in past one year
• Reduced life expectancy